NO20090875L - Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner - Google Patents

Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Info

Publication number
NO20090875L
NO20090875L NO20090875A NO20090875A NO20090875L NO 20090875 L NO20090875 L NO 20090875L NO 20090875 A NO20090875 A NO 20090875A NO 20090875 A NO20090875 A NO 20090875A NO 20090875 L NO20090875 L NO 20090875L
Authority
NO
Norway
Prior art keywords
nmdar
fusion peptide
component
inhibiting interaction
nmda receptor
Prior art date
Application number
NO20090875A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Meyer
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of NO20090875L publication Critical patent/NO20090875L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20090875A 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner NO20090875L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015911A EP1884521A1 (de) 2006-07-31 2006-07-31 Fusionspeptide zur Hemmung der Wechselwirkung zwischen den neuronalen NDMA Rezeptor und damit NMDAR interagierende Proteine
PCT/EP2007/006619 WO2008014917A1 (en) 2006-07-31 2007-07-25 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Publications (1)

Publication Number Publication Date
NO20090875L true NO20090875L (no) 2009-02-25

Family

ID=37084687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090875A NO20090875L (no) 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Country Status (15)

Country Link
US (1) US20090281036A1 (de)
EP (2) EP1884521A1 (de)
JP (1) JP2009545543A (de)
KR (1) KR20090033868A (de)
CN (1) CN101490081A (de)
AT (1) ATE509948T1 (de)
AU (1) AU2007280717A1 (de)
BR (1) BRPI0714783A2 (de)
CA (1) CA2653438A1 (de)
HR (1) HRP20080648A2 (de)
IL (1) IL195536A0 (de)
MX (1) MX2009001095A (de)
NO (1) NO20090875L (de)
RU (1) RU2009106710A (de)
WO (1) WO2008014917A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2043671T3 (da) 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
AU2009246316B2 (en) * 2008-05-16 2014-06-19 Nono Inc. Treatment for epilepsy
CN102202677A (zh) * 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
EP2440230B1 (de) 2009-06-10 2020-11-11 NoNO Inc. Behandlungsverfahren zur behandlung von neurologischen erkrankungen
CA2765171C (en) 2009-06-10 2018-10-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
PT2723363T (pt) 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
US9579358B2 (en) 2011-10-10 2017-02-28 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
WO2013088382A1 (en) * 2011-12-13 2013-06-20 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
KR102166374B1 (ko) * 2012-11-28 2020-10-15 노노 인코포레이티드 Tat-nr2b9c의 동결건조된 제형
US20140296164A1 (en) * 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206563A2 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3063168B1 (de) 2013-10-30 2019-03-06 University of Western Australia Neuroprotektive peptide
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
CA2941357A1 (en) * 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
JPWO2016035820A1 (ja) * 2014-09-02 2017-06-22 学校法人東京理科大学 中枢作用性ペプチド誘導体及び医薬組成物
CN104650242A (zh) * 2015-01-13 2015-05-27 河南科技大学 一种融合多肽及其制备方法和应用
JP6958913B2 (ja) 2015-11-06 2021-11-02 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 心停止の処置のためのペプチドおよび方法
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
US11208446B2 (en) * 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
WO2018184059A1 (en) * 2017-04-02 2018-10-11 Interk Peptide Therapeutics Limited Compositions and methods for prophylaxis or treatment of pain
EP3650460A4 (de) 2017-07-05 2021-03-17 Biocells (Beijing) Biotech Co., Ltd. Pharmazeutisch annehmbares salz eines polypeptids und seine verwendung
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
US20220265837A1 (en) 2019-07-11 2022-08-25 Xiamen University Complex for intracellular delivery of molecules
WO2021135647A1 (zh) 2019-12-31 2021-07-08 厦门大学 用于胞内递送分子的多聚化递送系统
CA3166998A1 (en) * 2020-01-09 2021-07-15 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN113999286B (zh) * 2020-07-28 2024-08-02 中国科学院武汉病毒研究所 一种靶向肠道病毒2c蛋白的广谱抗肠道病毒的多肽抑制剂及应用
CN114539358B (zh) * 2020-11-19 2023-09-15 中国科学院大连化学物理研究所 一种多肽及制备方法与应用
CN112853559B (zh) * 2020-12-31 2021-10-08 盐城师范学院 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
US20250333442A1 (en) * 2021-12-27 2025-10-30 Ajou University Industry-Academic Cooperation Foundation Novel cell-permeable peptide and use thereof
CN118359717A (zh) * 2023-01-18 2024-07-19 中国科学院脑科学与智能技术卓越创新中心 抗nmda受体自身免疫性脑炎新型抗体及其用途
CN119390848A (zh) * 2023-09-07 2025-02-07 湖南中晟全肽生物科技股份有限公司 具有神经保护作用的肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7410998A (en) * 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP1578365A4 (de) * 2002-11-14 2009-09-23 Arbor Vita Corp Molekulare interaktionen in neuronen

Also Published As

Publication number Publication date
BRPI0714783A2 (pt) 2013-07-30
EP2046821B1 (de) 2011-05-18
US20090281036A1 (en) 2009-11-12
ATE509948T1 (de) 2011-06-15
EP2046821A1 (de) 2009-04-15
KR20090033868A (ko) 2009-04-06
AU2007280717A1 (en) 2008-02-07
RU2009106710A (ru) 2010-09-10
MX2009001095A (es) 2009-02-10
IL195536A0 (en) 2011-08-01
JP2009545543A (ja) 2009-12-24
HRP20080648A2 (hr) 2009-02-28
WO2008014917A1 (en) 2008-02-07
EP1884521A1 (de) 2008-02-06
CN101490081A (zh) 2009-07-22
CA2653438A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
IL195536A0 (en) Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
EP2617431A3 (de) Polypeptid-Inhibitoren von HSP27-Kinase und Verwendungen dafür
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20080246L (no) Anti-IGF1R-antistofformuleringer
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
EA200802128A1 (ru) Новые нутрицевтические композиции
BRPI0413644A (pt) métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
WO2006066024A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
SI1848458T1 (sl) Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov
WO2008100290A3 (en) Recombinant rhinovirus vectors
WO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
AP2006003544A0 (en) Amino acids with affinity for the alpha2delta-protein.
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2005007682A3 (en) A peptide and a pharmaceutical composition, and their medical applications
WO2007047962A3 (en) Insecticides that target protein kinase a (pka)
WO2004113566A3 (en) Disease related protein network
BRPI0513715A (pt) veìculo para medicamentos para obtenção de biodisponibilidade oral
EP1575578A4 (de) Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application